Prospective Sinonasal Cancer Multi-institution Study
Recruiting
- Conditions
- Sinonasal Carcinoma
- Registration Number
- NCT04755855
- Lead Sponsor
- Mayo Clinic
- Brief Summary
This is a multi-institution prospective study of patients with sinonasal malignancies. The goal of this study is to learn more about the course of sinonasal cancer, treatment outcomes, and patient quality of life. In addition, central mutational and genomic analysis of tumor tissue will be evaluated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Subjects between the ages of 30 days (non-inclusive) and 99 years (inclusive)
- Patients with a diagnosis of sinonasal cancer
- Patients undergoing treatment at Mayo Clinic
Read More
Exclusion Criteria
- Healthy individuals
- Unwilling to sign the informed consent
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Oncologic outcomes as measured by overall survival, disease specific survival and recurrence free survival Through study completion, an average of 5 years
- Secondary Outcome Measures
Name Time Method Describe the molecular foundation of sinonasal malignancies utilizing RNA sequencing to identify transcriptomic tumor profiles Through study completion, an average of 5 years Quality of life outcomes including the University of Washington Quality of Life Questionnaire (UW-QOL v4) and the Sinonasal Outcome Test 22 (SNOT22) Through study completion, an average of 5 years
Trial Locations
- Locations (1)
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States